Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.39USD
15 Dec 2017
Change (% chg)

$0.11 (+3.35%)
Prev Close
$3.28
Open
$3.32
Day's High
$3.41
Day's Low
$3.27
Volume
888,577
Avg. Vol
292,471
52-wk High
$4.47
52-wk Low
$2.81

Chart for

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule,... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $950.48
Shares Outstanding(Mil.): 270.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations

01 Nov 2017

BRIEF-Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

* Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

25 Sep 2017

BRIEF-Amarin names Mark Salyer chief commercial officer

* Amarin appoints Mark W. Salyer to new position of chief commercial officer

13 Sep 2017

BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned

* Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

14 Aug 2017

BRIEF-Amarin reports Q2 loss per share $0.05

* Amarin reports second quarter 2017 financial results and provides update on operations

02 Aug 2017

Competitors

Earnings vs. Estimates